Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.76 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | MLYCD | O95822 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 4/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | NAAA | Q02083 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4046696 | 0.94 | KMT2A (0.69) | GAAKMT2AHSD17B10NPC1RAB9A | |
| SCHEMBL11652211 | 0.93 | KMT2A (0.67) | GAAKMT2AHSD17B10NPC1RAB9A | |
| SCHEMBL17865783 | 0.90 | MLYCD (0.73) | GAAKMT2AHSD17B10NPC1RAB9A | |
| SCHEMBL18082335 | 0.89 | NPC1 (0.71) | GAAKMT2AHSD17B10NPC1RAB9A | |
| SCHEMBL14197819 | 0.88 | GPR139 (0.68) | GAAKMT2AHSD17B10NPC1RAB9A | |
| SCHEMBL27386734 | 0.86 | NPC1 (0.61) | GAAKMT2AHSD17B10NPC1RAB9A | |
| SCHEMBL3377096 | 0.86 | NPC1 (0.66) | GAAKMT2AHSD17B10NPC1RAB9A | |
| SCHEMBL8507006 | 0.86 | NPC1 (0.66) | GAAKMT2AHSD17B10NPC1RAB9A | |
| SCHEMBL8506869 | 0.86 | NPC1 (0.66) | GAAKMT2AHSD17B10NPC1RAB9A | |
| SCHEMBL16105693 | 0.85 | KMT2A (0.67) | GAAKMT2AHSD17B10NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118043327-A | FGFR inhibitors and methods of use thereof | 思康睿奇(上海)药业有限公司 | 2024-05-14 | — | — | CN | claimed |
| CN-111423396-B | sEH inhibitor, and preparation method and application thereof | 沈阳药科大学 | 2023-01-06 | — | — | CN | claimed |
| EP-3911645-B1 | 5-MEMBERED HETEROARYL COMPOUNDS CONTAINING A HYDROXAMATE MOIETY AND THEIR USE | UNIV LILLE (FR) | 2022-12-07 | — | — | EP | claimed |
| CN-108473429-B | ROR gamma modulators | 领先制药控股公司 | 2021-09-10 | — | — | CN | claimed |
| US-11015180-B2 | Carboxyesterase polypeptides for amide coupling | CODEXIS, INC. (US) | 2021-05-25 | — | — | US | claimed |
| CN-112028928-A | Cosmetic containing phytic acid amide salt | 青岛姿之妍化妆品科技有限责任公司 | 2020-12-04 | — | — | CN | claimed |
| EP-3724325-A1 | CARBOXYESTERASE POLYPEPTIDES FOR AMIDE COUPLING | Codexis, Inc. (US) | 2020-10-21 | — | — | EP | claimed |
| CN-111699250-A | Carboxyesterase polypeptides for amide coupling | 科德克希思公司 | 2020-09-22 | — | — | CN | claimed |
| WO-2019118557-A1 | CARBOXYESTERASE POLYPEPTIDES FOR AMIDE COUPLING | CODEXIS, INC. (US) | 2019-06-20 | — | — | WO | claimed |
| US-20190177707-A1 | CARBOXYESTERASE POLYPEPTIDES FOR AMIDE COUPLING | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2019-06-13 | — | — | US | claimed |
| EP-3303291-A1 | ROR GAMMA (ROR ) MODULATORS | Lead Pharma Holding B.V. (NL) | 2018-04-11 | — | — | EP | claimed |
| WO-2016193452-A1 | ROR GAMMA (RORγ) MODULATORS | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2016-12-08 | — | — | WO | claimed |
| WO-2013007663-A1 | 2-BENZYLSULFANYL[1,3,4]-OXADIAZOLE DERIVATIVES, AND MEDICAL USE THEREOF | Technische Universität Darmstadt (DE) | 2013-01-17 | — | — | WO | claimed |
| EP-2032141-A1 | INHIBITORS OF JANUS KINASES | Merck & Co., Inc. (US) | 2009-03-11 | — | — | EP | claimed |
| WO-2008107677-A2 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | SENEXIS LIMITED (GB) | 2008-09-12 | — | — | WO | claimed |
| WO-2007145957-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2007-12-21 | — | — | WO | claimed |
| EP-1370260-A2 | AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-12-17 | — | — | EP | claimed |
| WO-2002066035-A2 | AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-08-29 | — | — | WO | claimed |
| US-20260014115-A1 | SMALL MOLECULE BCL-2 FUNCTIONAL CONVERTERS AS CANCER THERAPEUTICS | OREGON STATE UNIVERSITY (US) | 2026-01-15 | — | — | US | disclosed |
| EP-0339976-A1 | Anti-tumour agents | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014115-A1 | SMALL MOLECULE BCL-2 FUNCTIONAL CONVERTERS AS CANCER THERAPEUTICS | BCL2, BAX, BCL2A1 | GAA 4848/4885KMT2A 3281/4885HSD17B10 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.